Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin DDI with Rifampicin
NCT03063580Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotagliflozin in diabetes mellitus (DM), sponsored by Sanofi. Primary endpoints: Maximum plasma concentration up to 96 hours, Area under the concentration-time curve from 0 to the last quantifiable concentration up to 96 hours and 1 more. Started Feb 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03063580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063580.